Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus nab-paclitaxel and carboplatin as neoadjuvant therapy for resectable esophageal cancer
ChiCTR2000041081Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab, paclitaxel and carboplatin in esophageal cancer, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Major pathological response. Started Nov 2020; status: recruiting.
02
Drugs
sintilimabpaclitaxelcarboplatin
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2000041081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041081.